Advertisement

Johnson & Johnson's Cordis subsidiary touts positive 1-year findings for its Incraft AAA stent graft system in treatment of patients with abdominal aortic aneurysms.

Cordis logo

Johnson & Johnson (NYSE:JNJ) subsidiary Cordis this month unveiled 1-year clinical findings from a study of its Incraft AAA stent graft system in treating abdominal aortic aneurysms.

The Incraft AAA system is under investigation through the company's multi-center, prospective, non-randomized INNOVATION study in AAA patients, according to a press release.

Advertisement
Advertisement